Last mentioned: Mar 5, 2026
Potential EU Launch
Target window for commercial availability of iopofosine I 131 in Europe.
Target Commercialization
Anticipated EU launch for iopofosine I 131 treatment of WM.
EMA Submission
Planned filing of Conditional Marketing Authorization for iopofosine I 131.
EMA Submission
Target window for filing the CMA for iopofosine I 131 in the European Union.
CLR 125 Data
Expected early data readout from Phase 1b study in triple-negative breast cancer.
CLR 125 Data Readout
Expected early data from the Phase 1b study in Triple Negative Breast Cancer.
Financial Results
Company reports 2025 results and provides corporate update.
Annual Results Announcement
CEO James Caruso provides corporate updates and confirms regulatory timelines.
Fiscal Year End
Cellectar completes a year of pipeline advancement and platform validation.
Fiscal Year End
Cellectar concludes a year focused on pipeline execution and supply chain strengthening.
Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform.
Cellectar Biosciences has announced its 2025 year-end results, highlighting a strategic shift toward European commercialization for its lead radiotherapeutic, iopofosine I 131. The company remains on track for a Q3 2026 regulatory submission to the EMA, while simultaneously advancing its Phase 1b study for CLR 125 in triple-negative breast cancer.